Tom Mickelson is Vice President, Dermatology & Rheumatology Global Therapeutic Area Leader at Janssen Research & Development, LLC. In this role, he leads the global commercial strategy for Janssen’s Dermatology and Rheumatology portfolio and pipeline and creates the short and long-term end to end disease area strategy in close collaboration with functional and global counterparts. He continues to drive commercialized portfolio growth and differentiation while preparing for the launch of future assets and works in close partnership with Research & Development and Business Development to identify future opportunities to transform outcomes for patients and maximize Janssen’s portfolio in strategic and innovative ways.
In his prior role at Janssen as Director of Marketing for U.S. Dermatology, Tom drove new and innovative strategies coupled with disciplined execution to accelerate the competitiveness of TREMFYA® today and into the future.
Prior to his time with Johnson & Johnson, Tom had an extensive career with Eli Lilly and Company where he held a number of leadership positions across the organization, both in the U.S. and abroad. He began his career with several cross-functional roles across numerous therapeutic areas including sales management, thought leader liaison, strategy and operations, six sigma, and marketing. He then moved outside of the U.S. where he led the Lilly and Boehringer Ingelheim alliance team based in Germany as the Global Brand Director for JARDIANCE® (empagliflozin).
He was then named Chief Marketing Officer for the China affiliate, where he led the transformational efforts in marketing and commercial capabilities. In his transition back to the U.S., he became the Head of Tanezumab and the Lilly-Pfizer alliance team where he led the commercialization and launch efforts for the U.S. affiliate. Tom then worked as the U.S. marketing leader for TALTZ® (ixekizumab).
Tom has his undergraduate degree from Bradley University and an MBA from Northwestern Kellogg School of Management.
Follow Tom on LinkedIn here.